Cohance Life
Drug Manufacturers - Specialty & Generic · COHANCE
Mid CapHealthcareHigh Growth
Dr. V. Prasada Raju
Managing Director · Pragmatic
Company DNA
Performance-Driven
About
Cohance Life is a Mid Cap company in the Healthcare sector, listed on NSE as COHANCE. With a market cap of ₹11K Cr and revenue of ₹1K Cr, it is currently in the High Growth phase. Known for its Performance-Driven culture and Fast-Follower approach to innovation, the company operates at a Startup-Speed pace. High-growth CDMO operations requiring rigorous quality compliance and efficient delivery cycles. Its strategic mandate: Needs to scale complex chemical manufacturing processes while maintaining rigorous global quality compliance standards.
FAQ
What kind of company is Cohance Life?
Cohance Life is a Mid Cap Healthcare company (COHANCE) in the High Growth phase with a market cap of ₹11K Cr. It is classified as Performance-Driven in culture.
What is Cohance Life's culture and work environment like?
Cohance Life has a Performance-Driven culture with Fast-Follower innovation DNA and a Startup-Speed pace of execution. Employee brand: Demanding Machine. Customer relationship style: B2B-Enterprise. High-growth CDMO operations requiring rigorous quality compliance and efficient delivery cycles.
Who leads Cohance Life?
Cohance Life is led by Dr. V. Prasada Raju (Managing Director), a Pragmatic leader with 23 years of experience.
What are Cohance Life's financials?
Cohance Life reported revenue of ₹1K Cr in FY25 with a 5-year revenue CAGR of -3.6%. Operating margin: 28%. Market cap: ₹11K Cr.
Culture & Strategy
CulturePerformance-Driven
InnovationFast-Follower
PaceStartup-Speed
PurposePurpose-Blended
CustomerB2B-Enterprise
EmployeeDemanding Machine
BrandTechnical-Expert
LifecycleHigh Growth
High-growth CDMO operations requiring rigorous quality compliance and efficient delivery cycles.
Mandate
Needs to scale complex chemical manufacturing processes while maintaining rigorous global quality compliance standards.
Needs to scale complex chemical manufacturing processes while maintaining rigorous global quality compliance standards.
Financials
Revenue FY25₹1K Cr
PAT FY25₹268 Cr
Rev CAGR 5Y-3.6%
OPM28%
NPM22.9%
ROE15.8%
ROCE12.3%
P/E58.5
Fwd P/E28.8
P/B3
D/E11.5
Mkt Cap₹11K Cr
Promoter64%
Institutional24.8%
Similar Culture
Could You Lead Cohance Life?
Take the Genome Benchmark →